Research data has shown that tamoxifen therapy prolonged disease-free periods and overall survival rates in patients with estrogen receptor (ER)-positive breast tumors but had little benefit for patients with ER-negative tumors. In addition, patients who were ER-negative but progesterone receptor (PR)-positive also improved with tamoxifen therapy.
